Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray

NEW YORK – Foundation Medicine said on Wednesday that the US Food and Drug Administration has approved its FoundationOne CDx test as a companion diagnostic for alpelisib (Novartis' Piqray) in combination with fulvestrant (AstraZeneca's Faslodex) for the treatment of postmenopausal women, as well as men, with hormone receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based treatment.

The decision expands the use of FoundationOne CDx, which has already been approved by the FDA as a companion diagnostic for more than a dozen other targeted drugs, most recently olaparib (AstraZeneca's and Merck's Lynparza).

About 40 percent of patients with HR+/HER2- breast cancer have a mutation in PIK3CA, making it the most commonly mutated gene in this type of cancer. Professional guidelines were updated in September to recommend testing for PIK3CA mutations in patients with this breast cancer.

Foundation Medicine, a unit of Roche, said it has an ongoing collaboration with Novartis to support the development of companion diagnostics for the pharma company's cancer drugs.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.